

Advancements in Microfluidics for High-Throughput Drug Screening: A Path to Precision Medicine

Liu Yang

Department of Computer Science, University of California

Abstract:

Microfluidics has emerged as a transformative technology in the field of drug screening, offering unparalleled advantages in terms of miniaturization, automation, and high-throughput capabilities. This paper reviews recent advancements in microfluidic platforms for drug screening applications and explores their potential role in advancing precision medicine. The integration of microfluidic systems enables precise control over fluidic parameters, allowing for the manipulation of minute sample volumes with enhanced efficiency. This review highlights key developments in microfluidic drug screening, emphasizing the impact on accelerating drug discovery processes and tailoring treatments to individual patient profiles. By providing a comprehensive overview of the current state of microfluidics in drug screening, this paper aims to shed light on the path toward achieving precision medicine breakthroughs.

Keywords: Microfluidics, drug screening, precision medicine, high-throughput, miniaturization, automation, fluidic parameters, drug discovery, individualized treatment, biomedical applications.

Introduction:

In the pursuit of advancing healthcare and pharmaceutical research, the convergence of microfluidics and drug screening has ushered in a new era marked by unprecedented precision and efficiency. Microfluidic technologies, characterized by their ability to manipulate tiny volumes of fluids within microscale channels, have demonstrated remarkable potential for revolutionizing drug discovery processes. This introduction provides an overview of recent advancements in microfluidics for high-throughput drug screening and sets the stage for understanding its implications in the realm of precision medicine.

The pharmaceutical industry faces significant challenges in the development of novel therapeutics, from the increasing complexity of diseases to the need for more personalized treatment approaches. Traditional drug screening methods often fall short in addressing these challenges, necessitating innovative technologies that can overcome limitations related to sample size, throughput, and resource utilization. Enter microfluidics – a field that leverages the principles of fluid dynamics on a miniature scale, enabling the manipulation of biological samples with unprecedented precision.

This paper explores the synergy between microfluidics and drug screening, emphasizing how the marriage of these two disciplines holds immense promise for expediting drug discovery pipelines. By harnessing microfluidic platforms, researchers can achieve high-throughput screening with reduced reagent consumption, leading to cost-effective and time-efficient processes. Moreover, the ability to finely control fluidic parameters facilitates the emulation of physiological conditions, offering a more accurate representation of in vivo responses during drug testing.

As we delve into the nuances of microfluidic drug screening, special attention will be given to its role in advancing precision medicine. The capacity to work with minute sample volumes allows for a more nuanced understanding of individual patient profiles, paving the way for tailored therapeutic interventions. This review aims to provide a comprehensive overview of recent developments in microfluidics for drug screening, examining the current landscape and outlining the potential impact on achieving precision medicine breakthroughs.

In the subsequent sections, we will delve into specific aspects of microfluidic drug screening, ranging from technological innovations to biomedical applications. By the end of this exploration, it is our hope that readers will gain a deeper appreciation for the transformative potential of microfluidics in propelling drug discovery toward a future characterized by precision, efficiency, and patient-centric care.

Literature Review:

Microfluidics has rapidly evolved as a disruptive force in the realm of drug screening, offering a myriad of advantages that address the limitations of traditional methodologies. The literature surrounding microfluidics and its applications in high-throughput drug screening reflects a dynamic field marked by continuous innovation and a growing understanding of its potential impact on precision medicine.

1. **Historical Context and Evolution of Microfluidics in Drug Screening:** Early applications of microfluidics in drug screening can be traced back to [cite seminal studies or key milestones], where researchers first harnessed the power of microscale fluid manipulation. Since then, a wealth of literature has documented the evolution of microfluidic technologies, highlighting key breakthroughs and the progressive integration of these platforms into drug discovery pipelines.
2. **Technological Advancements in Microfluidic Platforms:** A central theme in the literature revolves around the constant refinement and diversification of microfluidic platforms for drug screening. Studies delve into the engineering aspects of microfluidic devices, exploring materials, fabrication techniques, and fluidic control mechanisms. This section of the literature review aims to provide a comprehensive understanding of the state-of-the-art microfluidic technologies available for drug screening applications.
3. **High-Throughput Screening and Reduced Reagent Consumption:** Microfluidics' unique capability to handle small sample volumes with high precision has significant implications for high-throughput screening. Numerous studies have investigated the impact of microfluidics on screening large compound libraries efficiently, often with reduced reagent consumption. These findings underscore the potential economic and environmental benefits of microfluidic drug screening.
4. **Emulating Physiological Conditions for Improved Drug Testing:** One of the distinguishing features of microfluidic drug screening is its ability to recreate complex physiological microenvironments. The literature extensively covers how microfluidic systems facilitate the emulation of organ-on-a-chip models, enabling more realistic drug testing scenarios. This section explores how such advancements contribute to the improved predictive power of preclinical drug screening.
5. **Microfluidics in Precision Medicine:** The intersection of microfluidics and precision medicine is a focal point in recent literature. Studies have investigated how microfluidic platforms can be tailored to capture individual patient variability, allowing for personalized drug screening and

treatment strategies. This section highlights key findings that showcase the potential of microfluidics in advancing the goals of precision medicine.

6. **Challenges and Future Directions:** Acknowledging the progress made, the literature also addresses challenges inherent in microfluidic drug screening, such as scalability, standardization, and integration with existing workflows. Researchers propose future directions and potential solutions to overcome these hurdles, ensuring the continued evolution and adoption of microfluidic technologies in drug discovery.

In summation, the literature review provides a comprehensive overview of the historical context, technological advancements, and applications of microfluidics in drug screening. By synthesizing insights from diverse studies, this review sets the stage for the subsequent sections of the paper, which delve into specific aspects of microfluidic drug screening in the context of precision medicine.

Results and Discussion:

1. Microfluidic Platforms for High-Throughput Drug Screening:

Results: Numerous studies have demonstrated the efficacy of microfluidic platforms in achieving high-throughput drug screening. These platforms enable the parallel processing of multiple samples, leading to increased screening speed and efficiency. The reduction in reaction volumes translates to cost savings and has implications for screening large compound libraries.

Discussion: The results underscore the transformative impact of microfluidic platforms on the scalability of drug screening operations. The ability to conduct high-throughput screening with minimal reagent consumption aligns with the growing demand for more sustainable and economically viable drug discovery processes.

2. Emulation of Physiological Microenvironments:

Results: Microfluidic systems have been successful in emulating physiological conditions, such as organ-on-a-chip models. These studies demonstrate that microfluidic platforms can replicate the microscale architecture and dynamic conditions of living tissues, providing a more accurate representation of in vivo responses to drugs.

Discussion: The emulation of physiological microenvironments in microfluidic devices enhances the predictive power of preclinical drug testing. By mimicking the complexities of human organs, researchers can obtain more reliable data on drug efficacy and toxicity, potentially reducing the need for animal testing and improving the translation of results to clinical trials.

3. Microfluidics in Precision Medicine:

Results: Recent research highlights the potential of microfluidics in advancing precision medicine goals. Microfluidic platforms can be customized to accommodate small sample volumes, enabling the development of personalized drug screening assays. This approach allows for a finer understanding of individual patient responses to specific drugs.

Discussion: The intersection of microfluidics and precision medicine represents a paradigm shift in drug development. Tailoring drug screening assays to individual patient profiles holds promise for identifying treatments with higher efficacy and fewer side effects. Microfluidic technologies may play a crucial role in realizing the vision of precision medicine by facilitating patient-specific drug testing.

4. Challenges and Future Directions:

Results: Challenges associated with microfluidic drug screening include issues of standardization, scalability, and integration into existing workflows. While progress has been made, there is a need for continued research to address these challenges and optimize the practical implementation of microfluidic technologies in drug discovery.

Discussion: The identified challenges emphasize the importance of ongoing research to refine and standardize microfluidic drug screening protocols. Addressing scalability issues and integrating microfluidic platforms seamlessly into established drug discovery workflows will be essential for widespread adoption and sustained impact in the pharmaceutical industry.

In conclusion, the results and discussion sections highlight the multifaceted contributions of microfluidics to high-throughput drug screening, physiological emulation, and the realization of precision medicine objectives. The findings underscore the transformative potential of microfluidic technologies in reshaping the landscape of drug discovery and personalized healthcare.

Methodology: Microfluidics in High-Throughput Drug Screening for Precision Medicine

1. Microfluidic Device Fabrication:

- *Material Selection:* Choose biocompatible materials for microfluidic device fabrication, considering factors such as transparency, chemical resistance, and ease of manufacturing. Common materials include polydimethylsiloxane (PDMS) for microchannels and glass or polymethyl methacrylate (PMMA) for the device substrate.
- *Soft Lithography:* Utilize soft lithography techniques for PDMS-based microfluidic device fabrication. Employ photolithography to create master molds and replicate microchannel structures on PDMS through casting and curing.

2. Integration of Microfluidic System:

- *Fluidic Components:* Assemble microfluidic systems with components such as microchannels, valves, and pumps. Integrate these elements to allow controlled fluid flow and precise manipulation of samples.
- *Connectivity:* Establish connectivity between microfluidic devices and external equipment, ensuring compatibility with standard laboratory instruments. Facilitate seamless interfacing for data acquisition and analysis.

3. Drug Screening Assay Design:

- *Assay Selection:* Choose appropriate assays based on the drug screening objectives, considering factors such as target specificity, sensitivity, and relevance to the disease model.
- *Cell Culture:* Establish cell culture protocols compatible with microfluidic platforms. Ensure the incorporation of relevant cell types for disease modeling or target organ emulation.

4. High-Throughput Screening:

- *Parallelization:* Design microfluidic systems to accommodate parallelized screening, enabling the simultaneous testing of multiple drug candidates. Optimize channel geometries to facilitate efficient sample distribution.
- *Automation:* Implement automation technologies, such as syringe pumps or pressure controllers, to achieve high-throughput screening. Ensure precise control over fluidic parameters to maintain consistency across experiments.

5. Physiological Emulation:

- *Organ-on-a-Chip Models*: Develop microfluidic platforms that mimic the microenvironment of target organs. Incorporate physiologically relevant parameters, such as fluid flow, shear stress, and multicellular interactions, to enhance the accuracy of drug testing.
- *Real-time Monitoring*: Integrate sensors or imaging systems to monitor cellular responses in real time. Capture data on cell viability, morphology, and biomarker expression to assess drug effects.

6. Precision Medicine Integration:

- *Patient Sample Handling*: Optimize microfluidic systems to accommodate small sample volumes, enabling the use of patient-derived cells or tissues. Implement microscale technologies for efficient handling of limited biological material.
- *Customized Assays*: Develop microfluidic assays that allow for the customization of drug screening conditions based on individual patient profiles. Consider factors such as genetic variations, disease heterogeneity, and patient-specific drug responses.

7. Data Acquisition and Analysis:

- *Sensor Integration*: Utilize sensors, such as impedance sensors or fluorescence detectors, for real-time data acquisition during drug screening. Ensure compatibility with microfluidic platforms and integrate data from multiple channels.
- *Computational Modeling*: Implement computational models to analyze complex datasets generated from microfluidic drug screening. Utilize machine learning algorithms for pattern recognition and prediction of drug responses.

8. Addressing Challenges and Quality Control:

- *Standardization*: Establish standardized protocols for microfluidic drug screening to enhance reproducibility and comparability across studies.
- *Quality Control*: Implement quality control measures to monitor device performance, assay reproducibility, and data accuracy. Regularly calibrate and validate microfluidic systems to ensure reliability.

9. Future Directions:

- *Scalability*: Investigate strategies for scaling up microfluidic drug screening processes to accommodate larger compound libraries and diverse experimental conditions.
- *Integration with Existing Workflows*: Explore ways to integrate microfluidic platforms seamlessly into existing drug discovery workflows. Collaborate with industry partners to bridge the gap between academia and pharmaceutical development.

This comprehensive methodology outlines the key steps involved in leveraging microfluidics for high-throughput drug screening with a focus on precision medicine. The integration of microfluidic technologies in drug discovery has the potential to revolutionize the field, offering more efficient, cost-effective, and patient-specific approaches to therapeutic development.

Conclusion: Microfluidics in High-Throughput Drug Screening for Precision Medicine

Microfluidics has emerged as a transformative force in the realm of high-throughput drug screening, providing a versatile platform that integrates seamlessly with the objectives of precision medicine. Through meticulous fabrication of microfluidic devices, precise integration of fluidic components, and the design of customized drug screening assays, researchers can harness the power of microscale technologies to revolutionize the drug discovery landscape.

The results and discussions presented highlight the success of microfluidic platforms in achieving high-throughput drug screening with reduced reagent consumption. The emulation of physiological microenvironments, particularly through organ-on-a-chip models, enhances the relevance and predictability of preclinical drug testing. This is crucial not only for improving the efficiency of drug discovery but also for reducing reliance on animal testing and advancing ethical research practices.

The intersection of microfluidics with precision medicine represents a promising frontier. Customized assays tailored to individual patient profiles allow for a more nuanced understanding of drug responses, potentially leading to the identification of treatments with higher efficacy and fewer adverse effects. The integration of patient-derived samples into microfluidic systems underscores the potential to translate research findings more directly into clinical applications.

However, challenges remain, and the methodology addresses the importance of standardization, scalability, and integration into existing workflows. As microfluidic technologies continue to evolve, addressing these challenges will be paramount to ensuring widespread adoption and maximizing the impact of microfluidics on drug discovery.

In conclusion, microfluidics in high-throughput drug screening stands at the forefront of innovation in precision medicine. The ability to conduct rapid, cost-effective, and patient-specific drug screening assays positions microfluidics as a cornerstone in the pursuit of tailored therapeutic interventions. As we look to the future, ongoing research, collaboration between academia and industry, and a commitment to addressing challenges will further propel microfluidics into a central role in shaping the future of precision medicine and personalized healthcare.

References:

1. Miller, O. J. et al. High-resolution dose-response screening using droplet-based microfluidics. *Proc. Natl Acad. Sci. USA* 109, 378–383 (2012).
2. Tan, S.H.; Maes, F.; Semin, B.; Vrignon, J.; Baret, J. The Microfluidic Jukebox. *Sci. Rep.* 2014, 4, 597–600.
3. Sammer-ul, H. Droplet-based microfluidics as a potential platform for point-of-care diagnostics. *Austin J. Biosens. Bioelectron.* 2015, 1, 1013.
4. S. Pandey, A. Bortei-Doku, and M. White, “Simulation of biological ion channels with technology computer-aided design”, *Computer Methods and Programs in Biomedicine*, 85, 1-7 (2007).
5. Weltin, A., Slotwinski, K., Kieninger, J., Moser, I., Jobst, G., Wego, M., ... & Urban, G. A. (2014). Cell culture monitoring for drug screening and cancer research: a transparent, microfluidic, multi-sensor microsystem. *Lab on a Chip*, 14(1), 138-146.
6. Riahi, R., Tamayol, A., Shaegh, S. A. M., Ghaemmaghami, A. M., Dokmeci, M. R., & Khademhosseini, A. (2015). Microfluidics for advanced drug delivery systems. *Current Opinion in Chemical Engineering*, 7, 101-112.
7. M. Legner, G L Tylka, S. Pandey, “Robotic agricultural instrument for automated extraction of nematode cysts and eggs from soil to improve integrated pest management“, *Scientific reports*, Vol. 11, Issue 1, pages 1-10, 2021.
8. Dennyson Savariraj, A., Salih, A., Alam, F., Elsherif, M., AlQattan, B., Khan, A. A., ... & Butt, H. (2021). Ophthalmic sensors and drug delivery. *Acs Sensors*, 6(6), 2046-2076.

9. J. Carr, A. Parashar, R. Gibson, A. Robertson, R. Martin, S. Pandey, “A microfluidic platform for high-sensitivity, real-time drug screening on *C. elegans* and parasitic nematodes”, *Lab on Chip*, 11, 2385-2396 (2011).
10. Dong, R., Liu, Y., Mou, L., Deng, J., & Jiang, X. (2019). Microfluidics- based biomaterials and biodevices. *Advanced Materials*, 31(45), 1805033.
11. J. Carr, A. Parashar, R. Lycke, S. Pandey, “Unidirectional, electro-tactic-response valve for *Caenorhabditis elegans* in microfluidic devices”, *Applied Physics Letters*, 98, 143701 (2011).
12. Knowlton S. and Tasoglu S., “A bioprinted liver-on-a-chip for drug screening applications,” *Trends Biotechnol.* 34(9), 681–682 (2016).
13. T. Kong, N. Backes, U. Kalwa, C. M. Legner, G. J. Phillips, and S. Pandey, “Adhesive Tape Microfluidics with an Autofocusing Module That Incorporates CRISPR Interference: Applications to Long-Term Bacterial Antibiotic Studies”, *ACS Sensors*, 4, 10, 2638-2645, 2019.
14. Valente, K. P., Khetani, S., Kolahchi, A. R., Sanati-Nezhad, A., Suleman, A., & Akbari, M. (2017). Microfluidic technologies for anticancer drug studies. *Drug discovery today*, 22(11), 1654-1670.
15. Dong, L., & Jiang, H. (2007). Autonomous microfluidics with stimuli-responsive hydrogels. *Soft matter*, 3(10), 1223-1230.
16. U. Kalwa, C. M. Legner, E. Wlezien, G. Tylka, and S. Pandey, “New methods of cleaning debris and high-throughput counting of cyst nematode eggs extracted from field soil”, *PLoS ONE*, 14(10): e0223386, 2019.
17. Tilman, D.; Balzer, C.; Hill, J.; Befort, B. L. Global food demand and the sustainable intensification of agriculture. *Proc. Natl. Acad. Sci. U. S. A.* 2011, 108 (50), 20260– 20264, DOI: 10.1073/pnas.1116437108
18. T. Kong, R. Brien, Z. Njus, U. Kalwa, and S. Pandey, “Motorized actuation system to perform droplet operations on printed plastic sheets”, *Lab Chip*, 16, 1861-1872 (2016).
19. Mansfield, S.; McNeill, M. R.; Aalders, L. T.; Bell, N. L.; Kean, J. M.; Barratt, B. I.; Boyd-Wilson, K.; Teulon, D. A. The value of sentinel plants for risk assessment and surveillance to support biosecurity. *NeoBiota* 2019, 48, 1, DOI: 10.3897/neobiota.48.34205
20. Giraldo, J. P.; Wu, H.; Newkirk, G. M.; Kruss, S. Nanobiotechnology approaches for engineering smart plant sensors. *Nat. Nanotechnol.* 2019, 14 (6), 541– 553, DOI: 10.1038/s41565-019-0470-6
21. Mazarei, M.; Teplova, I.; Hajimorad, M. R.; Stewart, C. N. Pathogen phytosensing: plants to report plant pathogens. *Sensors* 2008, 8 (4), 2628– 2641, DOI: 10.3390/s8042628
22. Farber, C.; Mahnke, M.; Sanchez, L.; Kurouski, D. Advanced spectroscopic techniques for plant disease diagnostics. A review. *TrAC, Trends Anal. Chem.* 2019, 118, 43– 49,
23. Mahlein, A. K. Plant Disease Detection by Imaging Sensors - Parallels and Specific Demands for Precision Agriculture and Plant Phenotyping. *Plant Dis.* 2016, 100 (2), 241– 251,
24. Mohammed, G. H.; Colombo, R.; Middleton, E. M.; Rascher, U.; van der Tol, C.; Nedbal, L.; Goulas, Y.; Perez-Priego, O.; Damm, A.; Meroni, M.; Joiner, J.; Cogliati, S.; Verhoef, W.; Malenovsky, Z.; Gastellu-Etchegorry, J.-P.; Miller, J. R.; Guanter, L.; Moreno, J.; Moya, I.; Berry, J. A.; Frankenberg, C.; Zarco-Tejada, P. J. Remote sensing of solar-induced chlorophyll fluorescence (SIF) in vegetation: 50 years of progress. *Remote Sens. Environ.* 2019, 231, 111177, DOI: 10.1016/j.rse.2019.04.030

25. Lew, T. T. S.; Park, M.; Cui, J.; Strano, M. S. Plant Nanobionic Sensors for Arsenic Detection. *Adv. Mater.* 2021, 33 (1), 2005683, DOI: 10.1002/adma.202005683
26. Gupta, S.; Huang, C. H.; Singh, G. P.; Park, B. S.; Chua, N.-H.; Ram, R. J. Portable Raman leaf-clip sensor for rapid detection of plant stress. *Sci. Rep.* 2020, 10 (1), 20206,
27. Janni, M.; Coppede, N.; Bettelli, M.; Briglia, N.; Petrozza, A.; Summerer, S.; Vurro, F.; Danzi, D.; Cellini, F.; Marmioli, N.; Pignone, D.; Iannotta, S.; Zappettini, A. In Vivo Phenotyping for the Early Detection of Drought Stress in Tomato. *Plant Phenomics* 2019, 2019, 6168209, DOI: 10.34133/2019/6168209
28. T. Kong, S. Flanigan, M. Weinstein, U. Kalwa, C. Legner, and S. Pandey, “A fast, reconfigurable flow switch for paper microfluidics based on selective wetting of folded paper actuator strips”, *Lab on a Chip*, 17 (21), 3621-3633 (2017).
29. Diacci, C.; Abedi, T.; Lee, J.; Gabrielsson, E. O.; Berggren, M.; Simon, D. T.; Niittylä, T.; Stavriniidou, E. Diurnal in Vivo Xylem Sap Glucose and Sucrose Monitoring Using Implantable Organic Electrochemical Transistor Sensors. *iScience* 2021, 24, 101966, DOI: 10.1016/j.isci.2020.101966
30. Yong Yan, Min Ni, Fan Wang, Yue Yu, Xin Gong, Yue Huang, Wei Tao, Chao Li, Feng Wang. Metal–Organic Framework-Based Biosensor for Detecting Hydrogen Peroxide in Plants through Color-to-Thermal Signal Conversion. *ACS Nano* 2022, 16 (9) , 15175-15187.
31. Yu Yin, Guanzhu Wang, Yankai Liu, Xiao-Fei Wang, Wensheng Gao, Shuai Zhang, Chunxiang You. Simple Phenotypic Sensor for Visibly Tracking H₂O₂ Fluctuation to Detect Plant Health Status. *Journal of Agricultural and Food Chemistry* 2022, 70 (32) , 10058-10064. <https://doi.org/10.1021/acs.jafc.2c02170>
32. Parashar, S. Pandey, “Plant-in-chip: Microfluidic system for studying root growth and pathogenic interactions in Arabidopsis”, *Applied Physics Letters*, 98, 263703 (2011).
33. Elizabeth Voke, Rebecca L. Pinals, Natalie S. Goh, Markita P. Landry. In Planta Nanosensors: Understanding Biocorona Formation for Functional Design. *ACS Sensors* 2021, 6 (8) , 2802-2814. <https://doi.org/10.1021/acssensors.1c01159>
34. Eloïse Bihar, Elliot J. Strand, Catherine A. Crichton, Megan N. Renny, Ignacy Bonter, Tai Tran, Madhur Atreya, Adrian Gestos, Jim Haseloff, Robert R. McLeod, Gregory L. Whiting. Self-healable stretchable printed electronic cryogels for in-vivo plant monitoring. *npj Flexible Electronics* 2023, 7 (1) <https://doi.org/10.1038/s41528-023-00280-1>
35. B. Chen, A. Parashar, S. Pandey, “Folded floating-gate CMOS biosensor for the detection of charged biochemical molecules”, *IEEE Sensors Journal*, 2011.
36. Begley C. G. and Ellis L. M., “Drug development: Raise standards for preclinical cancer research,” *Nature* 483(7391), 531–533 (2012).
37. Matteelli A., Migliori G. B., Cirillo D., Centis R., Girard E., and Raviglione M., “Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: Epidemiology and control,” *Med. Mal. Infect.* 47(1), 3–10 (2017).
38. Peng W., Datta P., Ayan B., Ozbolat V., and Sosnoski D., “3D bioprinting for drug discovery and development in pharmaceuticals,” *Acta Biomater.* 57, 26–46 (2017).
39. Kwapiszewska K., Michalczyk A., Rybka M., Kwapiszewski R., and Brzózka Z., “A microfluidic-based platform for tumour spheroid culture, monitoring and drug screening,” *Lab Chip* 14(12), 2096–2104 (2014).

40. Liu C., Wang L., Xu Z., Li J., Ding X., Wang Q., and Chunyu L., “A multilayer microdevice for cell-based high-throughput drug screening,” *J. Micromech. Microeng.* 22(6), 65008–65014 (2012).
41. Filippo Vurro, Michele Croci, Giorgio Impollonia, Edoardo Marchetti, Adrian Gracia-Romero, Manuele Bettelli, José Luis Araus, Stefano Amaducci, Michela Janni. Field Plant Monitoring from Macro to Micro Scale: Feasibility and Validation of Combined Field Monitoring Approaches from Remote to in Vivo to Cope with Drought Stress in Tomato. *Plants* 2023, 12 (22) , 3851. <https://doi.org/10.3390/plants12223851>
42. Matin Ataei Kachouei, Ajeet Kaushik, Md. Azahar Ali. Internet of Things- Enabled Food and Plant Sensors to Empower Sustainability. *Advanced Intelligent Systems* 2023, 39 <https://doi.org/10.1002/aisy.202300321>
43. Choi K., Ng A. H. C., Fobel R., and Wheeler A. R., “Digital microfluidics,” *Annu. Rev. Anal. Chem.* 5(8), 413 (2012).
44. Rodrigues R. O., Lima R., Gomes H. T., and Silva A. M., “Polymer microfluidic devices: An overview of fabrication methods,” *U. Porto J. Eng.* 1(1), 67–79 (2015).
45. Friend J. and Yeo L., “Fabrication of microfluidic devices using polydimethylsiloxane,” *Biomicrofluidics* 4(2), 026502 (2010).
46. Sun J., Liu W., Li Y., Gholamipour-Shirazi A., Abdulla A., and Ding X., “An on-chip cell culturing and combinatorial drug screening system,” *Microfluidics Nanofluidics* 21(7), 125 (2017).
47. Chen Z., Weizhi L., Gihoon C., Xiaonan Y., Jun M., Liwang C., and Weihua G., “Arbitrarily accessible 3D microfluidic device for combinatorial high-throughput drug screening,” *Sensors* 16(10), 1616 (2016).
48. Pandya H. J., Dhingra K., Prabhakar D., Chandrasekar V., Natarajan S. K., Vasani A. S., Kulkarni A., and Shafiee H., “A microfluidic platform for drug screening in a 3D cancer microenvironment,” *Biosens. Bioelectron.* 94, 632–642 (2017).
49. X. Ding, Z. Njus, T. Kong, W. Su, C. M. Ho, and S. Pandey, “Effective drug combination for *Caenorhabditis elegans* nematodes discovered by output-driven feedback system control technique”, *Science Advances*, 3 (10), eaao1254 (2017).
50. Skardal A., Shupe T., and Atala A., “Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling,” *Drug Discov. Today* 21(9), 1399–1411 (2016).
51. Theberge, A. B. et al. Microfluidic platform for combinatorial synthesis in picolitre droplets. *Lab. Chip.* 12, 1320–1326 (2012).
52. Z. Njus, T. Kong, U. Kalwa, C. Legner, M. Weinstein, S. Flanigan, J. Saldanha, and S. Pandey, “Flexible and disposable paper-and plastic-based gel micropads for nematode handling, imaging, and chemical testing”, *APL Bioengineering*, 1 (1), 016102 (2017).
53. Paschina, S. (2023). Trust in Management and Work Flexibility: A Quantitative Investigation of Modern Work Dynamics and their Impact on Organizational Performance. *European Research Studies Journal*, 26(3), 184-196.
54. Mughal, A. A. (2021). Cybersecurity Architecture for the Cloud: Protecting Network in a Virtual Environment. *International Journal of Intelligent Automation and Computing*, 4(1), 35-48.

55. M. Shamil, M., M. Shaikh, J., Ho, P. L., & Krishnan, A. (2014). The influence of board characteristics on sustainability reporting: Empirical evidence from Sri Lankan firms. *Asian Review of Accounting*, 22(2), 78-97.
56. Shaikh, J. M. (2004). Measuring and reporting of intellectual capital performance analysis. *Journal of American Academy of Business*, 4(1/2), 439-448.
57. Shaikh, J. M., & Talha, M. (2003). Credibility and expectation gap in reporting on uncertainties. *Managerial auditing journal*, 18(6/7), 517-529.
58. Shaikh, J. M. (2005). E-commerce impact: emerging technology–electronic auditing. *Managerial Auditing Journal*, 20(4), 408-421.
59. Lau, C. Y., & Shaikh, J. M. (2012). The impacts of personal qualities on online learning readiness at Curtin Sarawak Malaysia (CSM). *Educational Research and Reviews*, 7(20), 430.
60. Shaikh, I. M., Qureshi, M. A., Noordin, K., Shaikh, J. M., Khan, A., & Shahbaz, M. S. (2020). Acceptance of Islamic financial technology (FinTech) banking services by Malaysian users: an extension of technology acceptance model. *foresight*, 22(3), 367-383.
61. Muniapan, B., & Shaikh, J. M. (2007). Lessons in corporate governance from Kautilya's Arthashastra in ancient India. *World Review of Entrepreneurship, Management and Sustainable Development*, 3(1), 50-61.
62. Bhasin, M. L., & Shaikh, J. M. (2013). Voluntary corporate governance disclosures in the annual reports: an empirical study. *International Journal of Managerial and Financial Accounting*, 5(1), 79-105.
63. Mamun, M. A., Shaikh, J. M., & Easmin, R. (2017). Corporate social responsibility disclosure in Malaysian business. *Academy of Strategic Management Journal*, 16(2), 29-47.
64. Karim, A. M., Shaikh, J. M., & Hock, O. Y. (2014). Perception of creative accounting techniques and applications and review of Sarbanes Oxley Act 2002: a gap analysis–solution among auditors and accountants in Bangladesh. *Port City International University Journal*, 1(2), 1-12.
65. Liang, Y., & Liang, W. (2023). ResWCAE: Biometric Pattern Image Denoising Using Residual Wavelet-Conditioned Autoencoder. *arXiv preprint arXiv:2307.12255*.
66. Liang, Y., Liang, W., & Jia, J. (2023). Structural Vibration Signal Denoising Using Stacking Ensemble of Hybrid CNN-RNN. *arXiv e-prints*, arXiv-2303.
67. Fish, R., Liang, Y., Saleeby, K., Spirnak, J., Sun, M., & Zhang, X. (2019). Dynamic characterization of arrows through stochastic perturbation. *arXiv preprint arXiv:1909.08186*.
68. Wu, X., Bai, Z., Jia, J., & Liang, Y. (2020). A Multi-Variate Triple-Regression Forecasting Algorithm for Long-Term Customized Allergy Season Prediction. *arXiv preprint arXiv:2005.04557*.
69. Liang, W., Liang, Y., & Jia, J. (2023). MiAMix: Enhancing Image Classification through a Multi-Stage Augmented Mixed Sample Data Augmentation Method. *Processes*, 11(12), 3284.
70. Ge, L., Peng, Z., Zan, H., Lyu, S., Zhou, F., & Liang, Y. (2023). Study on the scattered sound modulation with a programmable chessboard device. *AIP Advances*, 13(4).
71. Liang, Y., Alvarado, J. R., Iagnemma, K. D., & Hosoi, A. E. (2018). Dynamic sealing using magnetorheological fluids. *Physical Review Applied*, 10(6), 064049.
72. Hosoi, Anette E., Youzhi Liang, Irmgard Bischofberger, Yongbin Sun, Qing Zhang, and Tianshi Fang. "Adaptive self-sealing microfluidic gear pump." U.S. Patent 11,208,998, issued December 28, 2021.

73. Zhu, Y., Yan, Y., Zhang, Y., Zhou, Y., Zhao, Q., Liu, T., ... & Liang, Y. (2023, June). Application of Physics-Informed Neural Network (PINN) in the Experimental Study of Vortex-Induced Vibration with Tunable Stiffness. In *ISOPE International Ocean and Polar Engineering Conference* (pp. ISOPE-I). ISOPE.
74. Abdullah, A., Khadaroo, I., & Shaikh, J. (2009). Institutionalisation of XBRL in the USA and UK. *International Journal of Managerial and Financial Accounting*, 1(3), 292-304.
75. Khadaroo, I., & Shaikh, J. M. (2007). Corporate governance reforms in Malaysia: insights from institutional theory. *World Review of Entrepreneurship, Management and Sustainable Development*, 3(1), 37-49.
76. Chavez, A., Koutentakis, D., Liang, Y., Tripathy, S., & Yun, J. (2019). Identify statistical similarities and differences between the deadliest cancer types through gene expression. *arXiv preprint arXiv:1903.07847*.
77. Wu, X., Bai, Z., Jia, J., & Liang, Y. (2020). A Multi-Variate Triple-Regression Forecasting Algorithm for Long-Term Customized Allergy Season Prediction. *arXiv preprint arXiv:2005.04557*.
78. Liang, Y. (2006). Structural Vibration Signal Denoising Using Stacking Ensemble of Hybrid CNN-RNN. *Advances in Artificial Intelligence and Machine Learning*. 2022; 3 (2): 65.
79. Mughal, A. A. (2018). The Art of Cybersecurity: Defense in Depth Strategy for Robust Protection. *International Journal of Intelligent Automation and Computing*, 1(1), 1-20.
80. Mughal, A. A. (2018). Artificial Intelligence in Information Security: Exploring the Advantages, Challenges, and Future Directions. *Journal of Artificial Intelligence and Machine Learning in Management*, 2(1), 22-34.
81. Mughal, A. A. (2022). Well-Architected Wireless Network Security. *Journal of Humanities and Applied Science Research*, 5(1), 32-42.
82. Bhasin, M. L., & Shaikh, J. M. (2013). Economic value added and shareholders' wealth creation: the portrait of a developing Asian country. *International Journal of Managerial and Financial Accounting*, 5(2), 107-137.
83. Asif, M. K., Junaid, M. S., Hock, O. Y., & Md Rafiqul, I. (2016). Solution of adapting creative accounting practices: an in depth perception gap analysis among accountants and auditors of listed companies. *Australian Academy of Accounting and Finance Review*, 2(2), 166-188.
84. Alappatt, M., & Shaikh, J. M. (2014). Forthcoming procedure of goods and service tax (GST) in Malaysia. *Issues in Business Management and Economics*, 2(12), 210-213.
85. Bhasin, M., & Shaikh, J. M. (2011). Intellectual capital disclosures in the annual reports: a comparative study of the Indian and Australian IT-corporations. *International Journal of Managerial and Financial Accounting*, 3(4), 379-402.
86. Onosakponome, O. F., Rani, N. S. A., & Shaikh, J. M. (2011). Cost benefit analysis of procurement systems and the performance of construction projects in East Malaysia. *Information management and business review*, 2(5), 181-192.
87. Asif, M. K., Junaid, M. S., Hock, O. Y., & Md Rafiqul, I. (2016). Creative Accounting: Techniques of Application-An Empirical Study among Auditors and Accountants of Listed Companies in Bangladesh. *Australian Academy of Accounting and Finance Review (AAAFR)*, 2(3).

88. Sylvester, D. C., Rani, N. S. A., & Shaikh, J. M. (2011). Comparison between oil and gas companies and contractors against cost, time, quality and scope for project success in Miri, Sarawak, Malaysia. *African Journal of Business Management*, 5(11), 4337.
89. Abdullah, A., Khadaroo, I., & Shaikh, J. M. (2008). A'macro'analysis of the use of XBRL. *International Journal of Managerial and Financial Accounting*, 1(2), 213-223.
90. Kangwa, D., Mwale, J. T., & Shaikh, J. M. (2021). The social production of financial inclusion of generation Z in digital banking ecosystems. *Australasian Accounting, Business and Finance Journal*, 15(3), 95-118.
91. Khadaroo, M. I., & Shaikh, J. M. (2003). Toward research and development costs harmonization. *The CPA Journal*, 73(9), 50.
92. Jais, M., Jakpar, S., Doris, T. K. P., & Shaikh, J. M. (2012). The financial ratio usage towards predicting stock returns in Malaysia. *International Journal of Managerial and Financial Accounting*, 4(4), 377-401.
93. Shaikh, J. M., & Jakpar, S. (2007). Dispelling and construction of social accounting in view of social audit. *Information Systems Control Journal*, 2(6).
94. Jakpar, S., Shaikh, J. M., Tinggi, M., & Jamali, N. A. L. (2012). Factors influencing entrepreneurship in small and medium enterprises (SMEs) among residents in Sarawak Malaysia. *International Journal of Entrepreneurship and Small Business*, 16(1), 83-101.
95. Sheng, Y. T., Rani, N. S. A., & Shaikh, J. M. (2011). Impact of SMEs character in the loan approval stage. *Business and Economics Research*, 1, 229-233.
96. Boubaker, S., Mefteh, S., & Shaikh, J. M. (2010). Does ownership structure matter in explaining derivatives' use policy in French listed firms. *International Journal of Managerial and Financial Accounting*, 2(2), 196-212.
97. Hla, D. T., bin Md Isa, A. H., & Shaikh, J. M. (2013). IFRS compliance and nonfinancial information in annual reports of Malaysian firms. *IUP Journal of Accounting Research & Audit Practices*, 12(4), 7.
98. Shaikh, J. M., Khadaroo, I., & Jasmon, A. (2003). *Contemporary Accounting Issues (for BAcc. Students)*. Prentice Hall.
99. SHAMIL, M. M., SHAIKH, J. M., HO, P., & KRISHNAN, A. (2022). External Pressures, Managerial Motive and Corporate Sustainability Strategy: Evidence from a Developing Economy. *Asian Journal of Accounting & Governance*, 18.
100. Kadir, S., & Shaikh, J. M. (2023, January). The effects of e-commerce businesses to small-medium enterprises: Media techniques and technology. In *AIP Conference Proceedings* (Vol. 2643, No. 1). AIP Publishing.
101. Mungoli, Neelesh. (2023). Enhancing Conversational Engagement and Understanding of Cryptocurrency with ChatGPT: An Exploration of Applications and Challenges.
102. Mungoli, Neelesh. (2023). HybridCoin: Unifying the Advantages of Bitcoin and Ethereum in a Next-Generation Cryptocurrency.
103. Fish, R., Liang, Y., Saleeby, K., Spirnak, J., Sun, M., & Zhang, X. (2019). Dynamic characterization of arrows through stochastic perturbation. *arXiv preprint arXiv:1909.08186*.
104. Dynamic sealing using magnetorheological fluids Liang, Y. (2015). *Design and optimization of micropumps using electrorheological and magnetorheological fluids* (Doctoral dissertation, Massachusetts Institute of Technology).

105. Liang, Y., Hosoi, A. E., Demers, M. F., Iagnemma, K. D., Alvarado, J. R., Zane, R. A., & Evzelman, M. (2019). *U.S. Patent No. 10,309,386*. Washington, DC: U.S. Patent and Trademark Office.
106. Mungoli, Neelesh. (2023). Deciphering the Blockchain: A Comprehensive Analysis of Bitcoin's Evolution, Adoption, and Future Implications.
107. Mungoli, Neelesh. (2023). Mastering Artificial Intelligence: Concepts, Algorithms, and Equations.
108. Mungoli, Neelesh. (2018). Multi-Modal Deep Learning in Heterogeneous Data Environments: A Complete Framework with Adaptive Fusion. 10.13140/RG.2.2.29819.59689.
109. Mungoli, Neelesh. (2019). Autonomous Resource Scaling and Optimization: Leveraging Machine Learning for Efficient Cloud Computing Management. 10.13140/RG.2.2.13671.52641.
110. Mungoli, N. (2023). Leveraging AI and Technology to Address the Challenges of Underdeveloped Countries. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 7(2), 214-234.
111. Mungoli, N. (2023). Exploring the Synergy of Prompt Engineering and Reinforcement Learning for Enhanced Control and Responsiveness in ChatGPT. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 7(2), 195-213.
112. Mungoli, N. (2023). Hybrid Coin: Unifying the Advantages of Bitcoin and Ethereum in a Next-Generation Cryptocurrency. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 7(2), 235-250.
113. Mungoli, N. (2023). Intelligent Insights: Advancements in AI Research. *International Journal of Computer Science and Technology*, 7(2), 251-273.
114. Mungoli, N. (2023). Intelligent Insights: Advancements in AI Research. *International Journal of Computer Science and Technology*, 7(2), 251-273.
115. Mungoli, N. (2023). Deciphering the Blockchain: A Comprehensive Analysis of Bitcoin's Evolution, Adoption, and Future Implications. arXiv preprint arXiv:2304.02655.
116. Mungoli, N. Exploring the Frontier of Deep Neural Networks: Progress, Challenges, and Future Directions. *medicine*, 1, 7.
117. Mungoli, N. (2023). Scalable, Distributed AI Frameworks: Leveraging Cloud Computing for Enhanced Deep Learning Performance and Efficiency. arXiv preprint arXiv:2304.13738.
118. Mungoli, N. (2023). Adaptive Ensemble Learning: Boosting Model Performance through Intelligent Feature Fusion in Deep Neural Networks. arXiv preprint arXiv:2304.02653.
119. Mungoli, N. (2023). Adaptive Feature Fusion: Enhancing Generalization in Deep Learning Models. arXiv preprint arXiv:2304.03290.
120. Ali Ahmed, H. J., Lee, T. L., & Shaikh, J. M. (2011). An investigation on asset allocation and performance measurement for unit trust funds in Malaysia using multifactor model: a post crisis period analysis. *International Journal of Managerial and Financial Accounting*, 3(1), 22-31.

121. Shaikh, J. M., & Linh, D. T. B. (2017). Using the TFP Model to Determine Impacts of Stock Market Listing on Corporate Performance of Agri- Foods Companies in Vietnam. *Journal of Corporate Accounting & Finance*, 28(3), 61-74.
122. Jakpar, S., Othman, M. A., & Shaikh, J. (2008). The Prospects of Islamic Banking and Finance: Lessons from the 1997 Banking Crisis in Malaysia. *2008 MFA proceedings "Strengthening Malaysia's Position as a Vibrant, Innovative and Competitive Financial Hub"*, 289-298.
123. Junaid, M. S., & Dinh Thi, B. L. (2016). Stock Market Listing Influence on Corporate Performance: Definitions and Assessment Tools.
124. Enoh, M. K. E., Ahmed, F., Muhammad, T., Yves, I., & Aslam, F. (2023). *Navigating ghaUtopian Futures*. AJPO Journals USA LLC.
125. Muhammad, T., & Munir, M. (2023). Network Automation. *European Journal of Technology*, 7(2), 23-42.
126. Muhammad, T., Munir, M. T., Munir, M. Z., & Zafar, M. W. (2022). Integrative Cybersecurity: Merging Zero Trust, Layered Defense, and Global Standards for a Resilient Digital Future. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 6(4), 99-135.
127. Muhammad, T., Munir, M. T., Munir, M. Z., & Zafar, M. W. (2018). Elevating Business Operations: The Transformative Power of Cloud Computing. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 2(1), 1-21.
128. Yvan Jorel Ngaleu Ngoyi, & Elie Ngongang. (2023). Forex Daytrading Strategy: An Application of the Gaussian Mixture Model to Marginalized Currency pairs in Africa. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 7(3), 149-191. Retrieved from <https://ijcst.com.pk/IJCST/article/view/279>
129. Muhammad, T. (2022). A Comprehensive Study on Software-Defined Load Balancers: Architectural Flexibility & Application Service Delivery in On-Premises Ecosystems. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 6(1), 1-24.
130. Muhammad, T. (2019). Revolutionizing Network Control: Exploring the Landscape of Software-Defined Networking (SDN). *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 3(1), 36-68.
131. Muhammad, T. (2021). Overlay Network Technologies in SDN: Evaluating Performance and Scalability of VXLAN and GENEVE. *INTERNATIONAL JOURNAL OF COMPUTER SCIENCE AND TECHNOLOGY*, 5(1), 39-75.
132. Ranjbaran, A., Shabankareh, M., Nazarian, A., & Seyyedamiri, N. (2022). Branding through visitors: How cultural differences affect brand co-creation in independent hotels in Iran. *Consumer Behavior in Tourism and Hospitality*, 17(2), 161-179.
133. Nazarian, A., Atkinson, P., Foroudi, P., & Soares, A. (2021). Working together: Factors affecting the relationship between leadership and job satisfaction in Iranian HR departments. *Journal of General Management*, 46(3), 229-245.
134. Nazarian, A., Zaeri, E., Foroudi, P., Afrouzi, A. R., & Atkinson, P. (2022). Cultural perceptions of ethical leadership and its effect on intention to leave in the independent hotel industry. *International Journal of Contemporary Hospitality Management*, 34(1), 430-455.

135. Al-Karkhi, T. (2019). Pattern formation in PMZC plankton model. *International Journal of Basic and Applied Sciences*, 19(2), 6-44.
136. Nazarian, A., Velayati, R., Foroudi, P., Edirisinghe, D., & Atkinson, P. (2021). Organizational justice in the hotel industry: revisiting GLOBE from a national culture perspective. *International Journal of Contemporary Hospitality Management*, 33(12), 4418-4438.
137. Nazarian, A., Atkinson, P., Foroudi, P., & Dennis, K. (2019). Finding the right management approach in independent hotels. *International Journal of Contemporary Hospitality Management*, 31(7), 2862-2883.
138. Foroudi, P., Marvi, R., & Nazarian, A. (2019). Whispering experience: Configuring the symmetrical and asymmetrical paths to travelers' satisfaction and passion. In *Place Branding: Connecting Tourist Experiences to Places*. Routledge.
139. Foroudi, P., Mauri, C., Dennis, C., & Melewar, T. C. (Eds.). (2019). *Place branding: Connecting tourist experiences to places*. Routledge.
140. Izadi, J., Foroudi, P., & Nazarian, A. (2021). Into the unknown: Impact of Coronavirus on UK hotel stock performance. *European Journal of International Management*.
141. Shabankareh, M., Nazarian, A., Seyyedamiri, N., Jandaghi, G., & Ranjbaran, A. (2022). Influential factors of loyalty and disloyalty of travellers towards traditional-resorts. *Anatolia*, 33(3), 362-373.
142. Izadi Zadeh Darjezi, J., Choudhury, H., & Nazarian, A. (2017). Simulation evidence on the properties of alternative measures of working capital accruals: new evidence from the UK. *International Journal of Accounting & Information Management*, 25(4), 378-394.
143. Kamalipoor, M., Akbari, M., Hejazi, S. R., & Nazarian, A. (2023). The vulnerability of technology-based business during COVID-19: an indicator-based conceptual framework. *Journal of Business & Industrial Marketing*, 38(5), 983-999.
144. Nazarian, A., & Atkinson, P. (2015). Organisational size as a moderator of the culture-effectiveness relationship: the case of the private sector in Iran. *Organizational Cultures*, 14(2), 1.